See analyst estimates and all valuation multiples for BioTech
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $722B | 12.7x | 29.8x | |
| $457B | 5.0x | 13.5x | |
| $446B | 7.5x | 16.3x | |
| $260B | 4.7x | 11.5x | |
| $229B | 3.6x | 7.9x | |
| $210B | 4.8x | 19.2x | |
| $195B | 5.6x | 10.6x | |
| $184B | 2.9x | 7.4x | |
| $157B | 5.5x | 10.8x | |
| $151B | 6.2x | 19.6x | |
| $132B | 2.8x | 8.7x | |
| $98.1B | 2.3x | 6.8x | |
| $95.5B | 8.1x | 23.1x | |
| $75.2B | 2.4x | 9.2x | |
| $73.1B | 4.6x | 13.8x | |
| $70.7B | 7.5x | 17.2x | |
| $69.2B | 1.3x | 6.1x | |
| $68.1B | 8.3x | 16.3x | |
| $63.4B | 2.6x | 9.0x | |
| $58.9B | 18.9x | 136.7x | |
| $56.2B | 4.0x | 11.5x | |
| $26.2B | 2.5x | 12.4x | |
| $25.1B | 1.8x | 5.9x | |
| $24.9B | 2.6x | 7.7x | |
| $24.4B | 1.8x | 8.9x | |
| $23.8B | 12.2x | 32.7x | |
| $23.7B | 9.6x | 41.0x | |
| $23.2B | 11.7x | -91.4x | |
| $22.6B | 6.6x | 22.4x | |
| $21.8B | 7.4x | 7.9x | |
| $14.3B | 4.1x | 10.9x | |
| $10.6B | 2.5x | 6.9x | |
| $10.6B | 14.0x | 45.1x | |
| $10.5B | 3.2x | 8.0x | |
| $10.4B | 5.1x | 13.7x | |
| $10.2B | 1.6x | 8.7x | |
| $10.1B | 2.5x | 10.4x | |
| $10.0B | n/a | n/a | |
| $10.0B | 1.6x | 12.7x | |
| $9.9B | 4.4x | 12.3x | |
| $9.8B | 8.0x | 12.2x | |
| $9.7B | 8427.0x | -303.3x | |
| $9.5B | 3.1x | 11.1x | |
| $9.5B | 1.8x | 14.0x | |
| $8.2B | n/a | n/a | |
| $6.0B | 18.0x | -61.9x | |
| $5.9B | 7.1x | 24.9x | |
| $5.8B | 4.2x | 15.5x | |
| $5.8B | 6.2x | -45.0x | |
| $5.7B | 31.8x | 91.2x | |
| $5.7B | 2.1x | 12.5x | |
| $5.6B | 3.9x | 11.6x | |
| $5.6B | 1.6x | 9.9x | |
| $5.6B | 10.1x | -32.6x | |
| $5.6B | 1.9x | 8.4x | |
| $5.4B | 1.6x | 7.2x | |
| $5.3B | 212.2x | -5.1x | |
| $5.3B | 2.3x | -1.4x | |
| $5.2B | 5.6x | 14.3x | |
| $5.2B | 11.6x | 39.0x | |
| $3.0B | 7.1x | 23.5x | |
| $2.6B | 5.0x | 46.8x | |
| $2.5B | n/a | n/a | |
| $2.2B | 1592.3x | -12.9x | |
| $2.1B | 10.0x | 39.8x | |
| $2.1B | 9.3x | 22.2x | |
| $2.1B | 5.8x | -19.6x | |
| $2.1B | 1.6x | 8.0x | |
| $2.1B | 1.8x | 6.0x | |
| $2.1B | 0.8x | 11.0x | |
| $2.1B | 3.6x | 29.8x | |
| $2.1B | 1.9x | 9.6x | |
| $2.1B | 472.2x | -4.8x | |
| $2.1B | 17.2x | 81.8x | |
| $2.1B | 6.7x | 12.9x | |
| $2.1B | n/a | n/a | |
| $2.0B | 56.8x | n/a | |
| $2.0B | 14.0x | n/a | |
| $2.0B | 105.5x | -165.8x | |
| $2.0B | 4.9x | 15.5x | |
| $2.0B | n/a | n/a | |
| $2.0B | 2.9x | 11.5x | |
| $2.0B | 6.7x | -32.2x | |
| $2.0B | 1.6x | 5.9x | |
| $1.9B | n/a | -4.1x | |
| $1.8B | 1.5x | 4.2x | |
| $834M | 1.2x | 5.0x | |
| $668M | 2.5x | 11.2x | |
| $637M | n/a | n/a | |
| $597M | 1.2x | 5.8x | |
| $515M | 1.8x | -33.3x | |
| $512M | 2.4x | n/a | |
| $375M | 1.4x | 7.6x | |
| $244M | n/a | n/a | |
| $124M | 1.1x | -28.6x | |
| $119M | n/a | n/a | |
| $92.4M | 1.6x | 17.5x | |
| $20.0M | 0.7x | n/a | |
| -$27.7M | n/a | n/a | |
| -$31.2M | n/a | n/a |